NCT05802485
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
Not Yet Recruiting · Not Applicable · Institut Paoli-Calmettes · registry updated 2023-04-06
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The study consists of a 25 ml blood sample collection: * Before the start of treatment * Approximately 2 months after the start of induction chemotherapy * At the end of induction chemotherapy * Prior to local treatment (radiotherapy, surgery) * At the time of tumor progression Collection of tumor material: * During the initial diagnostic biopsy * On the operating room in case of surgery * At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.
Inclusion
- Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)
- No previous treatment with surgery or chemotherapy
- Age \> 18 years
- General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)
- Therapeutic management at the Paoli-Calmettes Institute
- Signature of the informed consent specific to the PANDORE-PANC study
Exclusion
- Metastatic disease
- Pancreatic tumor of a histological type other than adenocarcinoma
- Other tumor under treatment or for which treatments have been completed for \< 1 year
- Pregnant or breastfeeding women
- Person in an emergency situation
- Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.